Delivery Order SPE2DB24D8002-SPE2DB25FJNDJ
Award Date
2/11/25
Potential Completion Date
2/12/25
Potential Value
$1.5K
Federal Agency
Defense Logistics Agency
Awardee
Dakota Drug, Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Anoka, MN, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract, SPE2DX15D8003|SPE2DX24F7C4A, valued at $5,961.44 to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract is for the delivery of pharmaceutical products, specifically 4563358030 - ELIQUIS 5 MG TABLET 60S, with a performance period through January 19, 2024. Dakota Drug, Inc. is a key supplier to the DLA Troop Support Medical division, holding a $999,999,999.00 Indefinite Delivery...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the provision of ELIQUIS 5 MG TABLET 60S. The contract, with a ceiling value of $4,973.50 and a performance period extending through October 30, 2024, is a firm fixed-price delivery order. It is not associated with any set-aside program. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA, identified as...
This is a federal contract award to Dakota Drug, Inc., a self-certified small disadvantaged business, by the Defense Logistics Agency (DLA) Troop Support Medical division. The $11,102.42 firm fixed-price delivery order contract is for the supply of ELIQUIS 5 MG TABLET 60S, a pharmaceutical product, with a performance period ending on July 6, 2022. The contract is not set-aside and is part of Dakota Drug's larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA under the ECAT...
This is a federal contract award to Dakota Drug, Inc., a self-certified small disadvantaged business, by the Defense Logistics Agency (DLA) for the delivery of Eliquis 5 mg tablets. The contract has a ceiling value of $1,484.40 and a period of performance through February 28, 2024. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA, identified as SPE2DB24D8001, valued at $999,999,999.00. This contract, part of the DLA Troop Support Medical's ECAT...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The contract, valued at $1,341.90, is for the delivery of ELIQUIS 2.5 MG TABLET 60S and has a firm fixed price pricing type. The contract has an ultimate completion date of January 16, 2025. Dakota Drug, Inc. is a key supplier of pharmaceutical products, medical supplies, and healthcare equipment to the U.S. federal government, with a focus on...
This is a $8,471.66 firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of Eliquis 5 mg tablets. The contract has an ultimate completion date of January 24, 2025. Dakota Drug, Inc. holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical's ECAT Generation V Program, which allows the company to provide a comprehensive range of...
This is a federal contract award from the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of Eliquis 5 mg tablets. The contract is a Firm Fixed Price Delivery Order with a ceiling value of $12,674.18 and a performance period ending on January 4, 2023. Dakota Drug, Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA, identified as SPE2DB24D8001 and valued at $999,999,999.00, as part of the DLA...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Dakota Drug, Inc., a self-certified small disadvantaged business. The $5,462.06 firm fixed-price contract is for the delivery of ELIQUIS 5 MG TABLET 60S, a pharmaceutical product. The contract has an ultimate completion date of January 13, 2025. Dakota Drug, Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical's ECAT Generation V Program, valued at $999,999,999.00, which allows...
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract to Dakota Drug, Inc., a self-certified small disadvantaged business, for the delivery of ELIQUIS 5 MG TABLET 60S. The contract has a ceiling value of $3,450.22 and a performance period ending on January 9, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) with the DLA, identified as SPE2DB24D8001, valued at $999,999,999.00. The IDC, which is part of the DLA Troop Support Medical's ECAT Generation V...
This federal contract award to Dakota Drug, Inc., a self-certified small disadvantaged business, was issued by the Defense Logistics Agency (DLA) Troop Support Medical division. The $5,560.45 firm-fixed-price delivery order is for the supply of Eliquis 5 mg tablets. This award is part of Dakota Drug, Inc.'s larger $999,999,999.00 Indefinite Delivery Contract (IDC) under the DLA Troop Support Medical's ECAT Generation V Program, which allows the company to provide a comprehensive range of...